Share Price, page-8932

reponse to Hottod - another great detailed post Hottod, and thanks for your insights into this business. Are you saying therefore that if we were to engage say Acadia for eg as a partner to conduct Ph III trials in the USA and with marketing rights for 2591 for Phelan McDermid syndrome, they'd require us to licence them for the other 3 indications as well? So it would be all or nothing kind of deal?

I still believe, that if our CEO believes we have the capability of doing a Ph III trial in the USA and of handling the discussions with the FDA to get approval for commercialisation, (provided the trials are successful), that this would be the better path for us. Then we licence a 3rd party to do the marketing for us. Surely that would result in higher upfront payments and royalties for us since we've taken a fair bit of the risk out of the proposition.

I'd still like to keep open the option of engaging a different partner for the RoW rights to 2591, at least until Acadia shows some significant progress on getting Daybue approved in a couple of different jurisdictions. I wonder what priority they are giving this in their internal deliberations.